The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why.

Merging with a former rival will bolster its capabilities. Recursion Pharmaceuticals (RXRX 0.75%) and Exscientia (EXAI 0.38%) made waves on Aug. 8 when they announced plans to merge into one business, forming the world's largest biotech devoted to doing drug development empowered by artificial intelligence (AI). The deal is expected to close sometime in early 2025. And now the bull thesis for Recursion's stock is more formidable than it was before. Here's what you need to know about what this merger is goin ...